Dr. Gustavo C. Rodriguez, MD

Years In Practice

20

Gender

Male

Field of Medicine

• Gynecologic Oncology

Specialty

• Gynecologic Oncology

Clinical Interests

• Cervical Cancer Treatment (Surgical And Chemotherapeutic)
• Clinical And Basic Research Of Ovarian And Uterine Cancer
• Ovarian Cancer Treatment (Surgical And Chemotherapeutic)
• Pelvic Masses/Advanced Laparoscopy
• Precancerous Conditions Of The Vulva, Vagina, And Cervix
• Uterine Cancer Treatment (Surgical And Chemotherapeutic)
• Vaginal Cancer Treatment (Surgical And Chemotherapeutic)
• Vulvar Cancer Treatment (Surgical And Chemotherapeutic)
• Women At Increased Risk Of Ovarian, Fallopian Tube And Uterine Cancer

Practice Information

Name

Division Of Gynecologic Oncology, NorthShore University Healthsystem

Web Site

www.northshore.org

Accepts Children 10 and Over

Education and Training

Medical School

University of Illinois

Internship

University of Illinois (Obstetrics and Gynecology)

Residency

University of Illinois (Obstetrics and Gynecology)

Fellowship

Duke University (Gynecologic Oncology)

2008 - Current

Clinical Associate Professor, Department of Obstetrics and Gynecology, University of Chicago; Director, Division of Gynecologic Oncology, NorthShore University HealthSystem

1989 - 1992

Fellowship - American Cancer Society Clinical Fellow Gynecologic Oncology Fellowship Training Program Department of Obstetrics and Gynecology Duke University Medical Center, Durham, NC

Board Certifications

• Obstetrics and Gynecology
  Gynecologic Oncology

Hospital Affiliations

• NorthShore University HealthSystem (Evanston, Highland Park, Glenbrook and Skokie Hospitals)

Professional Experience

2008 - Current

Clinical Associate Professor, Department of Obstetrics and Gynecology, University of Chicago; Director, Division of Gynecologic Oncology, NorthShore University HealthSystem

2001 - 2008

Associate Professor, Department of Obstetrics and Gynecology, Northwestern University Medical School; Director, Division of Gynecologic Oncology, NorthShore University HealthSystem

1998 - 2001

Associate Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC

1994 - 2001

Director, Cervical Dysplasia Clinic, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC

1990 - 1997

Assistant Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC

Professional Honors

• 2007 Matthews Family Professor of Gynecologic Oncology (Research
  Endowed Chair)
  
  2002 Research Career Development Award, Evanston Northwestern Healthcare
  
  2001 First Prize, Best Basic Science Poster, Society of Gynecologic Oncologists Meeting, Nashville, TN
  
  1999 First Prize, Plenary Presentation, Helene Harris Biannual Ovarian Cancer Meeting, Sweden
  
  2006 American Joint Committee on Cancer, Gynecologic Oncology Task Force (Appointed representative of the Society of Gynecologic Oncologists

Professional Societies and Committees

Memberships

• Society of Gynecologic Oncologists
  
  Gynecologic Oncology Group
  
  International Gynecologic Oncology Society
  
  American College of Obstetrics and Gynecology

Selected Publications

• 1. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr: Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva and vagina. Obstet and Gynecol 76:381-387, 1990.
  
  2. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC Jr: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164:669-674, 1991.
  
  3. Rodriguez GC, Berchuck A, Whitaker RS, Scholossman D, Clarke-Pearson DL, Bast RC Jr: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 164:745-750, 1991.
  
  4. Berchuck A, Rodriguez GC, Kinney RB, Soper JT, Clarke-Pearson DL, Bast RC Jr: Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164:15-21, 1991.
  
  5. Rodriguez GC, Clarke-Pearson DL: What is the appropriate preoperative and prenatal screen for hemostatic disorders? Obstetrics and Gynecology Forum, November 1991.
  
  6. Berchuck A, Rodriguez G, Olt GJ, Bent MP, Whitaker R, Arrick B, Clarke-Pearson DL, Bast RC Jr: Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol 166:676-84, 1992.
  
  7. Rodriguez GC, Soper JT, Berchuck A, Oleson J, Dodge R, Clarke-Pearson DL: Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy and surgery. J Clin Oncol 10:1553-60, 1992.
  
  8. Boente MP, Berchuck A, Rodriguez GC, Davidoff A, Whitaker BS, Xu FJ, Marks J, Clarke-Pearson DL, Bast RC: The effect of interferon Υ on epidermal growth factor expression in normal and malignant ovarian epithelial cells. Am J Obstet Gynecol 167:1877-1882, 1992.
  
  9. Wilson C, Rodriguez G: Current management of cervical epithelial neoplasia: ablation and excision. Postgraduate Ob & Gynecol 12(23):1992.
  
  10. Berchuck A, Kohler M, Boente M, Rodriguez G, Whitaker R, Bast RC Jr: Growth regulation and transformation of ovarian epithelium. Cancer 71:545-51, 1993.
  
  11. Rodriguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu FJ, Bast RC: Effect of antibodies and immunotoxins reactive with HER-2/neu on growth of breast and ovarian cancer cell lines. Am J Obstet Gynecol 168:228-32, 1993.
  
  12. Xu FJ, Rodriguez GC, Whitaker R, Boente MP, Berchuck A, McKenzie S, Houston L, Boyer CM, Bast RC: Antibody induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of HER-2/neu (c-erbB-2) gene product P185. Int J Cancer 53:401-408, 1993.
  
  13. Rodriguez G, Yaqub N, King ME: A comparison of the pipelle device and the vabra aspirator as measured by endometrial denudation in hysterectomy specimens: The pipelle device samples significantly less of the endometrial surface than the vabra aspirator. Am J Obstet Gynecol 168:55-9, 1993.
  
  14. Boente MP, Hurteau J, Rodriguez GC, Bast RC, Berchuck A: Biology of ovarian cancer. Current Opinion in Oncology 5:900-7, 1993.
  
  15. Woolas R, Xu FJ, Daly L, Soper JT, Berchuck A, Rodriguez G, Clarke-Pearson DL, Boyer CM, Bast RC Jr: Screening strategies for ovarian cancer. Diag Oncol 3:287-293, 1993.
  
  16. Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC Jr, Berchuck A: Transforming growth factor-β inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74:93-9, 1994.
  
  17. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC Jr: Overexpression of p53 is not a feature of benign and early stage borderline epithelial ovarian tumors. Gynecol Oncol 52:232-236, 1994.
  
  18. Soper JT, Evans AC, Conaway MR, Clarke-Pearson DL, Berchuck A, Rodriguez GC, Hammond CB. Evaluation of prognostic factors and staging in gestational trophoblastic tumor. Obstet Gynecol 84:969-973, 1994.
  
  19. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Stack M: Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian cancer. Int J Cancer 56:552-559, 1994.
  
  20. Young T, Rodriguez GC, Maser TL, Bast RC, Pizzo SV, Stack, MS: Coordinate expression of urinary type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Amer J Ob Gyn 170:1285-1296, 1994.
  
  21. Rodriguez GC, Hughes CL, Soper JT, Berchuck A, Tyrey L, Synan I, Dodge RK, Clarke-Pearson DL, Hammond CB: Serum progesterone for the exclusion of early pregnancy in women at risk for gestational trophoblastic neoplasia. Ob Gyn 84:794-797, 1994.
  
  22. Rodriguez GC, Clarke-Pearson DL, Soper JT, Berchuck A, Synan I, Dodge RK: The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Ob Gyn 83(3):445-448, 1994.
  
  
  23. Soper JT, Evans AC, Rodriguez G, Berchuck A, Clarke-Pearson DL, Hammond CB: Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Ob Gyn 83:113-117, 1994.
  
  24. Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB: 5-Day methotrexate for women with metastatic gestational trophoblastic disease. Gyn Onc 54:76-79, 1994.
  
  25. Rodriguez, G: Does thrombocytosis have any prognostic significance in cervical cancer? Gyn Onc 55:325-327, 1994.
  
  26. Soisson AP, Olt G, Soper JT, Berchuck A, Rodriguez G, Clarke-Pearson DL: Prevention of superficial wound separation with subcutaneous retention sutures. Gyn Onc 51:330-334, 1994.
  
  27. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC Jr., Berchuck A: Multivariate analysis of DNA ploidy, P53, and her/2-neu as prognostic factors in endometrial cancer. Cancer 73:2380-2385, 1994.
  
  28. Xu FJ, Yu YH, Daly L, Anselmino L, Hass GM, Berchuck A, Rodriguez GC, Soper JT, Clarke-Pearson DL, Hollis D: OVX1 as a marker for early-stage endometrial carcinoma. Cancer 73:1855-1858, 1994.
  
  29. Berchuck A, Elbendary A, Havrilesky LJ, Rodriguez GC, Bast RC Jr: Pathogenesis of Ovarian Cancers. J SGI 1(3):181-90, 1994.
  
  30. Hurteau JA, Rodriguez GC, Kay HH, Bentley RC, Clarke-Pearson, DL: Villoglandular adenocarcinoma of the cervix: A case report. Ob Gyn 85:906-8, 1995.
  
  31. Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, Bast RC Jr., Berchuck A: Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. Cancer Research 55:944-948, 1995.
  
  32. Woolas RP, Conaway MR, Xu FJ, Jacobs IJ, Yu YJ, Daley L, Davies AP, O'Briant K, Berchuck A, Soper JT, Clarke-Pearson DL, Rodriguez G, Oram DH, Bast RC Jr: Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59:111-116, 1995.
  
  
  33. LoCoco S, Covens A, Carney M, Franssen E, Dodge R, Rosen B, Osborne R, Kerr I, Buckman R, Soper J, Rodriguez G, DePetrillo A, Clarke-Pearson D, Berchuck A: Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American Comparative study. Gyn Onc 59:194-199, 1995.
  
  34. Soper JT, Evans AC, Rodriguez G, Berchuck A, Clarke-Pearson DL, Hammond CB: Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. Gynecol Oncol 56:421-424, 1995.
  
  35. Soper JT, Rodriguez G, Berchuck A, Clarke-Pearson DL: Long and short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery: Comparison of flap-specific complications. Gynecol Oncol 56:271, 1995.
  
  36. Cliby WA, Clarke-Pearson DL, Dodge R, Kohler MF, Rodriguez GC, Olt GJ, Soper JT, Berchuck A, Soisson AP: Acute morbidity and mortality associated with selective pelvic and paraaortic lymphadenectomy in the surgical stagingof endometrial adenocarcinoma. Gynecol Tech 1:19-25, 1995.
  
  37. Evans AC, Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez GC, Hammond CB: Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol 59:226-230, 1995.
  
  38. Liu JR, Conaway M, Rodriguez GC, Soper JT, Clarke-Pearson DL, Berchuck A: Relationship between race and interval to treatment in endometrial cancer. Obstet Gynecol 86:486-490, 1995.
  
  39. Havrilesky L, Elbendary A, Hurteau JA, Whitaker RS, Rodriguez GC, Berchuck A: Chemotherapy induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 85:1007-1010, 1995.
  
  40. Berchuck A, Anspach C, Evans AC, Soper JT, Rodriguez GC, Dodge R, Robboy S, Clarke-Pearson DL: Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Gynecol Oncol 59:20-24, 1995.
  
  41. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr., Pizzo SV, Stack MS: Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2. Gynecol Oncol 62:89-99, 1996.
  
  
  42. Rodriguez GC, Soper JT, Ho M, Dodge R, Berchuck A, Clarke-Pearson DL: Continuous versus interrupted Smead Jones abdominal wall closure. J. Gynecol Techniques 2:19-24, 1996.
  
  43. Rodriguez GC, Walmer D, Lessey B, Whitaker R, Krigman HR, Hughes CL. The effect of contraceptive progestins on the ovarian epithelium of Macaques: Cancer prevention through apoptosis? J Soc Gynecol Invest ;5: 271-276, 1998.
  
  44. Giuntoli R, Rodriguez G, Voynow J. Mucin gene expression in
  ovarian cancers. Cancer Research;58: 5546-5550, 1998.
  
  45. Alvarez A, Krigman H, Rodriguez G. The prognostic significance of angiogenesis in epithelial ovarian cancer. Clinical Cancer Research;5:587-91, 1999.
  
  46. Nagarsheth NP, Maxwell GL, Bentley RC, Rodriguez GC. Bilateral Pelvic Lymph Node Metastasis in a Case of FIGO Stage IA Adenocarcinoma of the Cervix. Gyn Oncol 77, 467-70, 2000
  
  47. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC, Jr., and Stack MS, Ph.D.: Regulation of invasion of epithelial ovarian cancer by transforming growth factor-Beta. Gyn Oncol 80, 245-253, 2001
  
  48. Alvarez AA, Maxwell GL, Rodriguez GC. Vacuum-assisted Closure for Cutaneous Gastrointestinal Fistula Management. Gyn Oncol 80, 413-416, 2001
  
  49. Angeles AA, Axelrod J, Whitaker RS, Bentley RC, Dodge RK, Rodriguez GC. Thrombospondin-1 Expression in Epithelial Ovarian Carcinoma: Association with p53 Status, Tumor Angiogenesis, and Survival. Gyn Oncol 82, 273-8, 2001
  
  50. Rodriguez GC, Nagarshef N, Rex C. Bentley, Walmer DK, Cline M, Whitaker RS, Eisner P, Berchuck A, Dodge R, Adams M, Hughes CL: Progestin Induction of Apoptosis in the Macaque Ovarian Epithelium: Differential Regulation of Transforming Growth Factor Beta. JNCI 94: 50-60, 2002
  
  
  
  51. Schildkraut J, Caligert B, Rodriguez GC. The Impact of Progestin and Estrogen Potency of Oral Contraceptives on Ovarian Cancer Risk. JNCI 94: 32-8, 2002
  
  
  52. Berchuck A, Brewer M, Rodriguez G, Campbell I. Ovarian Cancer Prevention. Gynecologic Oncology 88, S67-S70, 2003
  
  
  53. Havrilesky LJ. Alvarez AA. Sayer RA. Lancaster JM. Soper JT. Berchuck A. Clarke-Pearson DL. Rodriguez GC. Carney ME. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecologic Oncology. 88(1):51-7, 2003 Jan.
  
  
  54. Rodriguez G. New insights regarding pharmacologic approaches for ovarian cancer prevention. Hematology - Oncology Clinics of North America. 17(4):1007-20, 2003 Aug.
  
  
  55. Alvarez Secord A. Sayer R. Snyder SA. Broadwater G. Rodriguez GC. Berchuck A. Blackwell K. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecologic Oncology. 94(1):74-9, 2004 Jul.
  
  
  
  56. Walmer DK. Merisier D. Littman E. Rodriguez G. Venero N. Henderson M. Katz D. Edwards R. Portable colposcopy in low-resource settings. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 37 Suppl 3:S167-70, 2004 Oct.
  
  
  57. Andrew Berchuck, Joellen M. Schildkraut, Robert M. Wenham, Brian Calingaert, Shazia Ali, Amy Henriott, Susan Halabi, Gustavo C. Rodriguez, Dorota Gertig, David M. Purdie, Livia Kelemen, Amanda B. Spurdle, Jeffrey Marks, Georgia Chenevix-Trench. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiology, Biomarkers & Prevention. 13(12):2141-7, 2004 Dec.
  
  
  58. M. Alfonso, L. Adochiles, V. M. Hendrickson, D. K. Carver, G. C. Rodriguez, and H. John Barnes. Metastatic Adenocarcinoma in the Lungs of Older Laying Hens. Avian Diseases 49:430–432, 2005 Sep
  
  59. G.L. Maxwell, J.M. Schildkraut, B. Calingaert, J.I. Risinger, L. Dainty, P.A. Marchbanks, A. Berchuck, J.C. Barrett and G.C. Rodriguez. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecologic Oncology. 103(2):535-40, 2006 Nov.
  
  60. Alvarez Secord, A., Havrilesky, L.J., Carney, M.E., Soper, J.T., Clarke-Pearson, D.L., Rodriguez, G. C., Berchuck, A. A phase II study of weekly low dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. International Journal of Clinical Oncology. 12(1):31-6, 2007 Feb.
  
  61. Rodriguez GC, Rimel BJ, Watkin W, Turbov J, Barry C, Maxwell GL, Cline JM. Progestin Treatment Induces Apoptosis and Modulates TGF-β in the Uterine Endometrium. Cancer Epidemiology Biomarkers and Prevention. 17(3): 578-84, 2008 Mar.
  
  
  62. Alberts, Skates, Gail, Hensley, Miner, Mai, Loud, Minasian, Rodriguez, Basil, Boggess, Schwartz, Kelley, Green. A Prospective Study of Risk-Reducing Salpingo-Oopherectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A GOG Study”. Cancer Epidemiology Biomarkers and Prevention. 17(3): 594-604, 2008 Mar.
  
  
  
  63. Amy A. Hakim, Catherine P. Barry, H. John Barnes, Kenneth E. Anderson, James Petitte, Regina Whitaker, Jonathan M. Lancaster, Robert M.Wenham, Donna K. Carver, Jane Turbov, Andrew Berchuck, Levy Kopelovich, Gustavo C. Rodriguez. Ovarian Adenocarcinomas in the Laying Hen & Women Share Similar Alterations in p53, ras, & HER-2/neu . Cancer Prevention Research 2, 114, February 1, 2009.
  
  64. Sharma A, Belna J, Espat J, Rodriguez, Cannon VT, Hurteau JA. Effects of omega-3 fatty acids on components of the transforming growth factor beta-1 pathway: implication for dietary modification and prevention in ovarian cancer. Am J Obstet Gynecol 2009, vol 200, 516e1-516e6.
  
  65. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Rodriguez, Co-Author. Human Molecular Genetics, Vol. 18, 22, 2009, Pages 4442-4456
  
  66. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Gynecologic Oncology, Volume 115, Issue 3, December 2009, Pages 377-381
  

Additional Information

• Web-Based Publications
  
  1) Alvarez A, Rodriguez GC. Cervix Cancer Management Guidelines. Duke Web-EBM. June,2000
  
  2) Maxwell L, Rodriguez GC. Ovarian Cancer Management Guidelines. Duke Web-EBM. In Press, June 2001